Biotechnology
(GILD) Gilead Sciences Suffers Double Setbacks
Gilead Sciences, Inc (GILD) suffered two successive setbacks when the US Food and Drug Administration (FDA) issued complete response letters (CRLs) to the company’s HIV candidates, elvitegravir and cobicistat, for use as part of...1May2013 | vitalstocks | Comments Off | Continued
(VPHM) ViroPharma Drug Candidate Pipeline Progresses
ViroPharma Incorporated (VPHM) recently announced results from a phase II study of its candidate VP20621 (non-toxigenic Clostridium difficile), which is being developed to prevent recurrent C. difficile infections (CDI), a gastrointestinal...27Apr2013 | vitalstocks | Comments Off | Continued
(IMGN) ImmunoGen to Focus on Pipeline
ImmunoGen Inc.(IMGN) recently provided an update on its pipeline and maintained its outlook for fiscal year 2013 (ending June 30) at its recently held Analyst & Investor Day. ImmunoGen stated that its primary focus will...27Apr2013 | vitalstocks | Comments Off | Continued
(LIFE) Thermo Fisher Scientific Wins Life Technologies Corporation Takeover Battle
Finally, the much hyped takeover battle for Life Technologies Corporation (LIFE) came to an end on Monday with Thermo Fisher Scientific (TMO) emerging as the clear...27Apr2013 | vitalstocks | Comments Off | Continued
(ACHN) Achillion Pharmaceuticals’ HCV Candidates Progress
Achillion Pharmaceuticals, Inc. (ACHN) recently commenced international phase II studies on sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will assess an all-oral 12-week interferon-free...21Apr2013 | vitalstocks | Comments Off | Continued
(ARIA) Ariad Pharmaceuticals Presents Data on AP26113
Ariad Pharmaceuticals, Inc. (ARIA) recently presented pre-clinical data on AP26113. The data presented by the company revealed that AP26113 can inhibit clinically relevant anaplastic lymphoba kinase (ALK) mutants resistant to Pfizer...21Apr2013 | vitalstocks | Comments Off | Continued
(RPRX) Repros Therapeutics Gets Additional Patents
Repros Therapeutics Inc. (RPRX) recently announced that two additional patents covering its candidate, Androxal, have been issued. Both patents (8,372,887 and 8,377,991) related to metabolic consequences of low testosterone and the...21Apr2013 | vitalstocks | Comments Off | Continued
(REGN) Regeneron Pharmaceuticals Rated Neutral Again
We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron Pharmaceuticals (REGN). Our target price is $195.00 per share. Why the Reiteration? Regeneron reported higher-than-expected...18Apr2013 | vitalstocks | Comments Off | Continued
(BSTC) BioSpecifics Technologies Annouces Positive Data on Xiaflex
BioSpecifics Technologies (BSTC) recently announced positive top line data from a phase IIa study on Xiaflex for the potential treatment of frozen shoulder syndrome (FSS) in adults. BioSpecifics has a strategic partnership with Auxilium...18Apr2013 | vitalstocks | Comments Off | Continued
(GILD) Gilead Sciences Seeks FDA Approval
Gilead Sciences (GILD) recently submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval to market its hepatitis C Virus (HCV) candidate sofosbuvir (formerly GS-7977). Gilead is looking...18Apr2013 | vitalstocks | Comments Off | Continued
(BIIB) Biogen’s Tecfidera Approved by U.S. Food and Drug Administration
Tecfidera, Biogen Idec’s (BIIB) oral multiple sclerosis treatment, gained FDA approval recently for the first-line treatment of people with relapsing forms of multiple sclerosis. Biogen intends to launch the drug shortly. Results...30Mar2013 | vitalstocks | Comments Off | Continued
(THRX) Theravance Inks Deal for Vibativ
Theravance Inc. (THRX) recently entered into an agreement with UK-based Clinigen Group plc for the commercialization of Vibativ (telavancin) in the EU and several other European countries including Switzerland and Norway. As...24Mar2013 | vitalstocks | Comments Off | Continued
(AFFY) Affymax to Cut 75% of Workforce
Affymax, Inc. (AFFY) recently announced that it will reduce its total workforce by approximately 75% (230 employees). The company took this decision after it recalled all lots of Omontys (peginesatide) voluntarily along with its partner...23Mar2013 | vitalstocks | Comments Off | Continued
(CELG) Celgene Plans $600M Share Buyback
Celgene Corporation (CELG) recently entered into an accelerated share repurchase (ASR) agreement with an investment bank. The agreement will allow Celgene to repurchase around $600 million of its common stock. The move will boost...2Mar2013 | Shawn | Comments Off | Continued
(CHTP) Chelsea Therapeutics International Shows Encouraging News
Chelsea Therapeutics International Ltd. (CHTP) recently announced that it received written guidance from the Director of the Office of New Drugs at the US Food and Drug Administration (FDA) regarding the resubmission of the New Drug...1Mar2013 | Shawn | Comments Off | Continued
(SGEN) Seattle Genetics Starts SGN-CD19A Phase I Study
Seattle Genetics Inc. (SGEN) recently commenced two phase I clinical studies with its oncology candidate, SGN-CD19A. The two trials will assess the safety and anti-tumor response of SGN-CD19A in CD19-positive acute lymphoblastic leukemia...27Feb2013 | Shawn | Comments Off | Continued
(AMGN) The Picks and Shovels (and Levi’s) of Biotech
Yesterday marked the 184th birthday of an iconic American businessman – Levi Strauss My wife worked for Levi Strauss & Co. many years ago. They were a terrific company, with a strong commitment to product quality, their employees and their community. I was so impressed that...27Feb2013 | Shawn | Comments Off | Continued
(SGEN) Seattle Genetics’ Adcetris Earns Approval from Health Canada
Seattle Genetics Inc. (SGEN) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). Adcetris has been approved under Health Canada’s Notice of Compliance with conditions (NOC/c)...17Feb2013 | Shawn | Comments Off | Continued
(ARIA) ARIAD Pharmaceuticals Closes Offering of Shares
ARIAD Pharmaceuticals, Inc. (ARIA) recently announced the closure of its previously announced public offering. ARIAD Pharma priced the public offering of 15.3 million common shares at $19.60 per share, including 1.18 million shares...1Feb2013 | Shawn | Comments Off | Continued
(BIIB) Biogen Idec and Partner Elan Corporation Seek Label Expansion
Biogen Idec Inc. (BIIB) and partner Elan Corporation (ELN) recently submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency...23Jan2013 | Shawn | Comments Off | Continued
(XOMA) XOMA’s Gevokizumab Study Update
XOMA Corporation (XOMA) recently announced interim data from a phase II proof-of-concept (POC) study on gevokizumab, which is being developed for the treatment of inflammatory facial lesions in patients suffering from moderate to...15Jan2013 | Shawn | Comments Off | Continued
(MDVN) Ignore the Smartest Guys in the Room – All 8,600 of Them
Everyone loves the long ball. Home runs are exciting. Sammy Sosa and Mark McGwire’s steroid-fueled race in 1998 brought baseball back from the damage caused by the players’ strike a few years earlier. Tony Gwynn’s hitting singles and doubles en route to a .368 batting average in...15Jan2013 | InvestmentU | 0 comments | Continued
(OPTR) Optimer Pharmaceuticals’ Dificid Sales Look Good
Optimer Pharmaceuticals Inc. (OPTR) recently announced its preliminary sales for the fourth quarter and full year 2012. Optimer said that preliminary gross product sales of its only marketed product, Dificid (fidaxomicin),...15Jan2013 | Shawn | Comments Off | Continued
(ALNY) Alnylam Pharmaceuticals Provides Pipeline Update
Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its key “Alnylam 5×15” pipeline and partner program. Alnylam’s core product strategy, ‘Alnylam 5×15,’...9Jan2013 | Shawn | Comments Off | Continued
(AEZS) Aeterna Zentaris Candidate to be Evaluated Under Special Protocol Assessment
Aeterna Zentaris Inc. (AEZS) recently announced that its oncology candidate, AEZS-108 (doxorubicin peptide conjugate) will be evaluated under US Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA) in a phase III...5Jan2013 | Shawn | Comments Off | Continued
(MDVN) Medivation Analyst Neutral on Shares
We recently reiterated a Neutral recommendation on Medivation, Inc. (MDVN). Medivation received a major boost in late August when the FDA approved its prostate cancer treatment, Xtandi, several months ahead of the target date. Xtandi,...2Jan2013 | Shawn | Comments Off | Continued
(EBS) Emergent BioSolutions Inks Deal with VaxInnate
Specialty pharmaceutical company, Emergent BioSolutions (EBS), recently signed a license agreement to gain an exclusive manufacturing right to VaxInnate Corporation’s pandemic influenza vaccine candidate in the U.S. Financial terms...2Jan2013 | Shawn | Comments Off | Continued
(ARIA) ARIAD Pharmaceuticals Announced Ponatinib Data
ARIAD Pharmaceuticals (ARIA) recently announced positive data from the pivotal PACE study on ponatinib. ARIAD is evaluating the candidate for use in heavily pretreated patients, suffering from resistant and refractory chronic myeloid...17Dec2012 | Shawn | Comments Off | Continued
(ONXX) Onyx Pharmaceuticalsceuticals – Bull of the Day
We are upgrading Onyx Pharmaceuticals (ONXX) to Outperform based on the company’s strong third quarter results and improving prospects. Onyx reported solid third quarter results with revenues increasing 19.3%...7Dec2012 | vitalstocks | Comments Off | Continued
(ARIA) ARIAD Pharmaceuticals Sees Data Published on Drug Candidate
ARIAD Pharmaceuticals (ARIA) recently announced the publishing of results from a phase I dose-escalation study of ponatinib in the New England Journal of Medicine. Ponatinib, a tyrosine kinase...4Dec2012 | vitalstocks | Comments Off | Continued